Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00595868 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Varenicline in Ambivalent Smokers
A Phase 2 study, sponsored by University of Vermont Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
NCT00595868 is a Phase 2 study that has completed, run by University of Vermont Medical Center. The registered enrollment target is 220 participants.
The verdict
NCT00595868, a Phase 2 study, has completed, sponsored by University of Vermont Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether Varenicline can help ambivalent smokers (those who are interested in quitting at some point in the future but have no current plans to quit) to reduce their smoking and eventually quit.
Interventions
- DRUG Placebo
- DRUG Varenicline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00595868
The ClinicalTrials.gov registry entry for NCT00595868 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Vermont Medical Center, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00595868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00595868 about?
NCT00595868 is a clinical study titled "Efficacy of Varenicline in Ambivalent Smokers". The purpose of this study is to test whether Varenicline can help ambivalent smokers (those who are interested in quitting at some point in the future but have no current plans to quit) to reduce their smoking and eventually quit.
What is the current status of trial NCT00595868?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2008-03. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00595868?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG).
Who is sponsoring clinical trial NCT00595868?
This trial is sponsored by University of Vermont Medical Center, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.